Comparison of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in the primary prevention of myocardial infarction in hypertensive patients

被引：6
|
作者：
Baer, JT
Sauer, WH
Berlin, JA
Kimmel, SE
机构：
[1] Univ Penn, Sch Med, Ctr Clin Epidemiol & Biostat, Philadelphia, PA 19104 USA
[2] Univ Penn, Sch Med, Dept Biostat & Epidemiol, Philadelphia, PA 19104 USA
[3] Univ Penn, Sch Med, Dept Med, Div Cardiovasc, Philadelphia, PA 19104 USA
[4] Univ Penn, Sch Med, Dept Med, Ctr Educ & Res Theraeut, Philadelphia, PA 19104 USA
来源：
AMERICAN JOURNAL OF CARDIOLOGY | 2004年 / 94卷 / 04期
关键词：
D O I：
10.1016/j.amjcard.2004.04.063
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers have slightly different mechanisms of action. As such, it has been hypothesized that these 2 classes of medications differ in their ability to prevent myocardial infarction. In the present case-control study, we found no difference between angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in the primary prevention of nonfatal myocardial infarction among patients with hypertension. (C) 2004 by Excerpta Medica, Inc.
引用
收藏
页码：479 / 481
页数：3
相关论文
共 50 条
  • [21] Angiotensin-converting enzyme inhibitors versus angiotensin receptor blockers in hypertensive patients with myocardial infarction or heart failure: a systematic review and meta-analysis
    Toshio Ohtsubo
    Rei Shibata
    Hisashi Kai
    Ryuji Okamoto
    Eita Kumagai
    Hiroaki Kawano
    Akira Fujiwara
    Takanari Kitazono
    Toyoaki Murohara
    Hisatomi Arima
    Hypertension Research, 2019, 42 : 641 - 649
  • [22] Angiotensin-converting enzyme inhibitors versus angiotensin receptor blockers in hypertensive patients with myocardial infarction or heart failure: a systematic review and meta-analysis
    Ohtsubo, Toshio
    Shibata, Rei
    Kai, Hisashi
    Okamoto, Ryuji
    Kumagai, Eita
    Kawano, Hiroaki
    Fujiwara, Akira
    Kitazono, Takanari
    Murohara, Toyoaki
    Arima, Hisatomi
    HYPERTENSION RESEARCH, 2019, 42 (05) : 641 - 649
  • [23] Angiotensin Receptor Blockers as an Alternative to Angiotensin-Converting Enzyme Inhibitors in Patients with Acute Myocardial Infarction Undergoing Percutaneous Coronary Intervention
    Lim, Sungmin
    Choo, Eun Ho
    Choi, Ik Jun
    Ihm, Sang-Hyun
    Kim, Hee-Yeol
    Ahn, Youngkeun
    Chang, Kiyuk
    Jeong, Myung Ho
    Seung, Ki-Bae
    JOURNAL OF KOREAN MEDICAL SCIENCE, 2019, 34 (45)
  • [24] Are angiotensin-converting enzyme inhibitors and angiotensin 2 receptor blockers teratogenic?
    Morton, A. P.
    DIABETIC MEDICINE, 2013, 30 (10) : 1263 - 1264
  • [25] Angiotensin-Converting Enzyme Inhibitors vs. Angiotensin Receptor Blockers
    Tazkarji, Bachir
    Ganeshamoorthy, Ambika
    Auten, Beth
    AMERICAN FAMILY PHYSICIAN, 2015, 91 (03) : 193 - 194
  • [26] Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers for IgA nephropathy
    Dillon, JJ
    SEMINARS IN NEPHROLOGY, 2004, 24 (03) : 218 - 224
  • [27] Angiotensin-converting enzyme inhibitors, angiotensin II receptor blockers and coronavirus
    Verdecchia, Paolo
    Angeli, Fabio
    Reboldi, Gianpaolo
    JOURNAL OF HYPERTENSION, 2020, 38 (06) : 1190 - 1191
  • [28] Angioedema Related to Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers
    Nguyen, Timothy
    JNP-JOURNAL FOR NURSE PRACTITIONERS, 2018, 14 (09): : 690 - 691
  • [29] Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers for hypertension: are they equivalent?
    Kaplan, Norman M.
    JOURNAL OF THE AMERICAN SOCIETY OF HYPERTENSION, 2015, 9 (08) : 582 - 583
  • [30] Angiotensin Receptor Blockers and Angiotensin-Converting Enzyme Inhibitors for the Treatment of Hypertensive Patients With Type 2 Diabetes Mellitus
    Kawada, Tomoyuki
    CANADIAN JOURNAL OF DIABETES, 2020, 44 (01) : 4 - 4
12345